5090072 Technoclone Technoview Unfractionated Heparin UFH Control Low measurement assay detection reagent test kit

Technoview® UFH Control Low

$0.00

  • Catalog #: 5090072
  • Method: Chromogenic anti-Xa Assay Control
  • Packaging: Box/5x1ml
  • Type: Control
  • Use: Research Use Only (RUO)

Technoview® UFH Control Low is a plasma control with a low concentration (~0.2 IU/ml) of unfractionated heparin (UFH)  for use as a quality control sample in research measurements of heparin. It is optimized for use with anti-Xa chromogenic assays and is frequently used in conjunction with the Technoview® UFH high control and the Technoview® UFH calibrator set in the Technochrom® anti-Xa chromogenic assay.

Reagent Size Description
CON L 5 x 1 mL Technoview® UFH Control Low, human plasma, lyophilized, ~0.20 IU/mL UFH

Please consult the lot specific batch table provided with the controls for the exact concentrations in IU/mL of each control.

Stability after reconstitution: 18-25°C (open vial) / 48 hours, 2-8°C (closed vial) / 7 days, -20°C / 1 month.

Advantages

  • 5 vials per kit- provides control set with a long shelf life
  • Allows for the validation of calibration curves for the measurement of unfractionated heparin (UFH) in plasma
  • Optimized for use with anti-Xa (without exogeneous antithrombin) research assays

Calibrator Set Composition

  • 5 x 1 ml vials

Control material is lyophilized and prepared from pooled human citrated plasma supplemented with a low concentration of unfractionated heparin. The plasma contains stabilizers but no bactericide additives. It is calibrated against the 5th International Standard preparation for UFH 97/578.

Background

Heparin is a widely used antithrombotic agent that can be administered via an intravenous or subcutaneous route. It is naturally occurring and typically derived from bovine or porcine tissue. The anticoagulant effect of this sulfated glycosaminoglycan results from its binding to antithrombin (AT), the major inhibitor of the coagulation cascade. Binding induces a conformational change in the AT molecule, which greatly accelerates the AT inhibition of several coagulation proteases. The accelerated inhibition of thrombin and Factor Xa by heparin is the primary basis for its anticoagulation properties.

Two forms of heparin are used therapeutically: unfractionated heparin (UFH), with an average molecular weight (MW) of 15,000 and low molecular weight heparin (LMWH), with a MW between 4,000 and 6,500. The lower MW results in LMWH acting primarily on Factor Xa, whereas UFH efficiently inhibits both thrombin and Factor Xa. Both heparin forms should be monitored. UFH can be measured with an aPTT or an anti-Xa chromogenic assay while LMWH should be measured using and anti-Xa chromogenic assay. Note that this control is for research use only in the US and Canada.